Legend Biotech Corporation - American Depositary Shares (LEGN)
LEGN moved a median of -0.29% 30 minutes after news, and -0.16% by the close. How LEGN actually reacts to news — the realized, point-in-time move the market made, measured across 357 labeled events over the last three years with zero look-ahead.
LEGN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.17% | 42% | 357 |
| 30-min | -0.29% | 42% | 357 |
| 60-min | -0.36% | 41% | 357 |
| to close | -0.16% | 45% | 356 |
| Middle 50% of LEGN reactions | -1.20% to +0.52% |
|---|---|
| Median reaction (30-min) | -0.29% |
| Measured reactions | 357 |
Half of all Legend Biotech Corporation - American Depositary Shares news events land between -1.20% and +0.52% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How LEGN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 18 | -0.65% | 22% | -2.54% |
| Coverage initiations | 27 | -0.21% | 41% | -1.52% |
| Rating reiterations | 149 | -0.33% | 42% | 0.00% |
| Price-target raises | 14 | -0.24% | 36% | -0.90% |
| Price-target cuts | 16 | +0.13% | 50% | +0.30% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how LEGN ranks against every other measured name →
That’s how LEGN usually reacts — get an email when it moves on news →Email me when LEGN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LEGN's baseline. Nothing else.
Recent LEGN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Legend Biotech Corp For: Oct 15 | SEC filing · Form 6-K | SEC EDGAR | -1.30% | +2.86% | |
| Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy | Press release | GlobeNewswire | -1.30% | +2.86% | |
| Form 6-K Legend Biotech Corp For: Oct 13 | SEC filing · Form 6-K | SEC EDGAR | +1.59% | +1.53% | |
| Form S-8 Legend Biotech Corp | SEC filing · Form S-8 | SEC EDGAR | -0.85% | -1.06% | |
| Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma | Press release | GlobeNewswire | -0.77% | -1.48% | |
| Form 6-K Legend Biotech Corp For: Sep 24 | SEC filing · Form 6-K | SEC EDGAR | -0.46% | -1.95% | |
| Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion | Press release | GlobeNewswire | -0.46% | -1.95% | |
| Form 6-K Legend Biotech Corp For: Sep 24 | SEC filing · Form 6-K | SEC EDGAR | -0.46% | -1.95% | |
| Form 6-K Legend Biotech Corp For: Sep 15 | SEC filing · Form 6-K | SEC EDGAR | -1.88% | -5.00% | |
| Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer | Press release | GlobeNewswire | -1.88% | -5.00% | |
| Form 6-K Legend Biotech Corp For: Sep 14 | SEC filing · Form 6-K | SEC EDGAR | -1.44% | -0.96% | |
| Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting | Press release | GlobeNewswire | +0.46% | -2.59% | |
| Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference | Press release | GlobeNewswire | +0.97% | +2.77% | |
| Form 6-K Legend Biotech Corp For: Aug 18 | SEC filing · Form 6-K | SEC EDGAR | +0.23% | +1.57% | |
| ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments | Press release | GlobeNewswire | +0.07% | -3.37% | |
| Form 6-K Legend Biotech Corp For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -2.73% | +0.88% | |
| K2 Therapeutics Appoints Dr. Ying Huang as Chief Executive Officer and Announces $50 Million Seed Financing | Press release | GlobeNewswire | -2.73% | +0.88% | |
| Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights | Press release | GlobeNewswire | -2.73% | +0.88% | |
| Form 6-K Legend Biotech Corp For: Aug 06 | SEC filing · Form 6-K | SEC EDGAR | -0.70% | +3.75% | |
| Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results | Press release | GlobeNewswire | -1.46% | -0.52% | |
| Form 6-K Legend Biotech Corp For: Jul 27 | SEC filing · Form 6-K | SEC EDGAR | -4.89% | -6.14% | |
| Legend Biotech Announces CEO Transition | Press release | GlobeNewswire | -4.89% | -6.14% | |
| CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight | Press release | PR Newswire | -0.21% | -0.40% | |
| Form 6-K Legend Biotech Corp For: Jul 15 | SEC filing · Form 6-K | SEC EDGAR | -2.03% | -9.86% | |
| Form 6-K Legend Biotech Corp For: Jun 22 | SEC filing · Form 6-K | SEC EDGAR | -0.78% | +1.28% | |
| Legend Biotech Corporation Announces Pricing of Public Offering | Press release | GlobeNewswire | -1.34% | -6.12% | |
| Legend Biotech Corporation Announces Proposed Public Offering | Press release | GlobeNewswire | -1.34% | -6.12% | |
| Form 6-K Legend Biotech Corp For: Jun 15 | SEC filing · Form 6-K | SEC EDGAR | +0.76% | +0.17% | |
| Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Press release | GlobeNewswire | +0.76% | +0.17% | |
| Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Press release | GlobeNewswire | +0.76% | +0.17% | |
| Form 6-K Legend Biotech Corp For: Jun 02 | SEC filing · Form 6-K | SEC EDGAR | +6.65% | +41.44% | |
| Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) | Press release | GlobeNewswire | +7.13% | +43.68% | |
| Form 6-K Legend Biotech Corp For: Jun 01 | SEC filing · Form 6-K | SEC EDGAR | -3.12% | -4.21% | |
| Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026 | Press release | GlobeNewswire | -3.06% | -4.21% | |
| Form 6-K Legend Biotech Corp For: May 21 | SEC filing · Form 6-K | SEC EDGAR | +2.44% | +6.80% | |
| Legend Biotech Announces Presentations at ASCO 2026 | Press release | GlobeNewswire | +2.44% | +6.80% | |
| Form 6-K Legend Biotech Corp For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -0.49% | +14.74% | |
| Legend Biotech Reports First Quarter 2026 Results and Recent Highlights | Press release | GlobeNewswire | -0.49% | +14.74% | |
| Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth | Press release | GlobeNewswire | +1.70% | +12.43% | |
| Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results | Press release | GlobeNewswire | -0.98% | +0.81% | |
| Form 6-K Legend Biotech Corp For: Apr 14 | SEC filing · Form 6-K | SEC EDGAR | +2.58% | +4.71% | |
| GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth | Press release | PR Newswire | +1.06% | +1.22% | |
| Form 20-F Legend Biotech Corp For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.19% | +3.93% | |
| Form 6-K Legend Biotech Corp For: Mar 10 | SEC filing · Form 6-K | SEC EDGAR | +1.48% | +1.56% | |
| Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights | Press release | GlobeNewswire | +1.48% | +1.56% | |
| Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight | Press release | PR Newswire | +1.48% | +1.56% | |
| The International Myeloma Foundation Invites the Myeloma Community to Demonstrate the Spirit of #MoreThanMyeloma for 2026 Myeloma Action Month | Press release | GlobeNewswire | -1.12% | -2.23% | |
| Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results | Press release | GlobeNewswire | -3.76% | -2.21% | |
| Form 6-K Legend Biotech Corp For: Feb 06 | SEC filing · Form 6-K | SEC EDGAR | -0.93% | +0.17% | |
| GenScript Biotech Global Forum, "Scripting Possibilities", Convened AI and Biopharma Leaders in San Francisco | Press release | PR Newswire | +0.17% | -0.73% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LEGN section they belong to.
Where else LEGN is measured.
LEGN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Legend Biotech Corporation - American Depositary Shares's median reaction calculated?
Every labeled LEGN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 357 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of LEGN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LEGN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.